COVID‐19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia

• Published in: HemaSphere Vol. 7; no. 1; pp. e811 - n/a
• Main Authors: Shadman, Mazyar, Liu, Catherine, Eakle, Katherine, Hiew, Hwai J., Biondo, Juliana M.L., Ghia, Paolo, Mato, Anthony R.
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Lippincott Williams & Wilkins 01-01-2023; Wiley
• Subjects: Review
• DOI: 10.1097/HS9.0000000000000811
• EISSN: 2572-9241

Patients with chronic lymphocyticleukemia (CLL) typically have innate/adaptive immune system dysregulation, thus the protective effect of coronavirus disease 2019 (COVID‐19) vaccination remains uncertain. This prospective review evaluates vaccination response in these patients, including seropositivity rates by CLL treatment status, type of treatment received, and timing of vaccination. Antibody persistence, predictors of poor vaccine response, and severity of COVID‐19 infection in vaccinated patients were also analyzed. Practical advice on the clinical management of patients with CLL is provided. Articles reporting COVID‐19 vaccination in patients with CLL, published January 1, 2021–May 1, 2022, were included. Patients with CLL displayed the lowest vaccination responses among hematologic malignancies; however, seropositivity increased with each vaccination. One of the most commonly reported independent risk factors for poor vaccine response was active CLL treatment; others included hypogammaglobulinemia and age >65–70 years. Patients who were treatment‐naive, off therapy, in remission, or who had a prior COVID‐19 infection displayed the greatest responses. Further data are needed on breakthrough infection rates and a heterologous booster approach in patients with hematologic malignancies. Although vaccine response was poor for patients on active therapy regardless of treatment type, CLL management in the context of COVID‐19 should aim to avoid delays in antileukemic treatment, especially with the advent of numerous strategies to mitigate risk of severe COVID‐19 such as pre‐exposure prophylaxis, and highly effective antivirals and monoclonal antibody therapy upon confirmed infection. Patients with CLL should remain vigilant in retaining standard prevention measures such as masks, social distancing, and hand hygiene.